OSE Immunotherapeutics has reported positive results from the first-in-human Phase I/II study of OSE-279 to treat advanced solid tumours.

The dose escalation and expansion study intends to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D) of an anti-PD1 monoclonal antibody OSE-279.

In this study, OSE-279 will be evaluated as a monotherapy in advanced solid tumours with two possible administration rates.

Assessing antitumour activity, safety profile, pharmacokinetic (PK) and receptor occupancy or pharmacodynamic (PD) profile of OSE-279 are the secondary objectives of the study.

Thirteen patients with eight tumour types received OSE-279 100mg and 300mg every three weeks (q3w) or 600mg every six weeks (q6w).

The data, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston, showed a manageable safety profile with preliminary signs of efficacy in these patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

One confirmed partial response was observed in hepatocellular carcinoma patients who received a single dose of OSE-279 300mg.

The study also reported two yet unconfirmed partial responses in anal squamous cell carcinoma and undifferentiated pleomorphic sarcoma patients who received OSE-279 600mg.

Furthermore, stable disease longer than 16 weeks was observed in three patients with a disease control rate of 55%.

Both PK and PD profiles were consistent with modelling and PK profile showed good exposure and dose-proportionality.

Besides, receptor occupancy was maintained and within the boundaries of the simulation.

OSE-279 blocks both PD-L1 and PD-L2, the ligands of PD1 overexpressed by tumour cells and tumour microenvironment.

The company’s pipeline also includes Tedopi, OSE-127, FR-104/VEL-101, and OSE-172/BI 765063.